Last reviewed · How we verify
PHA-848125AC
At a glance
| Generic name | PHA-848125AC |
|---|---|
| Sponsor | Nerviano Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma (PHASE2)
- Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy (PHASE2)
- Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma (PHASE2)
- Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHA-848125AC CI brief — competitive landscape report
- PHA-848125AC updates RSS · CI watch RSS
- Nerviano Medical Sciences portfolio CI